TY - JOUR
T1 - Pharmacodynamic characteristics, safety profile, and interactions of CDK4/6 inhibitors (CDK4/6i) in HR1/HER2– advanced/metastatic breast cancer
AU - Savvidou, Antria
AU - Kitiri, Stavroula
AU - Zacharia, Lefteris
AU - Constantinidou, Anastasia
AU - Petrou, Christos C.
N1 - Publisher Copyright:
Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2024/7/5
Y1 - 2024/7/5
N2 - Targeted therapies such as cyclin-dependent kinase 4 and 6 inhibitors (CDK 4/6i) have improved the prognosis of hormone receptor-positive/human epidermal growth factor receptor-2 negative (HR1)/(HER2–) advanced/metastatic breast cancer (a/mBC) by combating the resistance observed with traditional endocrine therapy. Currently, palbociclib, ribociclib, and abemaciclib are the three medicinal products authorized by the European Medicines Agency and the Food and Drug Administration. In addition to their overall similarities, related to their primary molecular mechanism of action through CDK4/6 inhibition, they also exhibit significant pharmacodynamic differences that affect their efficacy and safety profile, which may, through further research, help in understanding predicted toxicity, safety, and interactions and assist in adjusting dosing regimens in daily clinical practice. This review article will examine the pharmacodynamic profile of CDK4/6 inhibitors, their efficacy and safety in the treatment of HR1/HER2– a/mBC.
AB - Targeted therapies such as cyclin-dependent kinase 4 and 6 inhibitors (CDK 4/6i) have improved the prognosis of hormone receptor-positive/human epidermal growth factor receptor-2 negative (HR1)/(HER2–) advanced/metastatic breast cancer (a/mBC) by combating the resistance observed with traditional endocrine therapy. Currently, palbociclib, ribociclib, and abemaciclib are the three medicinal products authorized by the European Medicines Agency and the Food and Drug Administration. In addition to their overall similarities, related to their primary molecular mechanism of action through CDK4/6 inhibition, they also exhibit significant pharmacodynamic differences that affect their efficacy and safety profile, which may, through further research, help in understanding predicted toxicity, safety, and interactions and assist in adjusting dosing regimens in daily clinical practice. This review article will examine the pharmacodynamic profile of CDK4/6 inhibitors, their efficacy and safety in the treatment of HR1/HER2– a/mBC.
UR - http://www.scopus.com/inward/record.url?scp=85198013219&partnerID=8YFLogxK
U2 - 10.1097/OP9.0000000000000054
DO - 10.1097/OP9.0000000000000054
M3 - Review article
AN - SCOPUS:85198013219
SN - 1783-3914
VL - 7
JO - European Journal of Oncology Pharmacy
JF - European Journal of Oncology Pharmacy
IS - 2
M1 - e54
ER -